Serological Interpretation of Rheumatic Manifestations in Brucellosis.

OBJECTIVES: To investigate the profile of autoimmune markers and to evaluate the status of vitamin D in the autoimmune process in brucellosis. STUDY DESIGN: Descriptive study. PLACE AND DURATION OF STUDY: Department of Rheumatology and Microbiology-Basic Immunology, Balikesir Ataturk City Hospital, Turkey, between June 2017 and December 2020. METHODOLOGY: Brucella seropositive patients (mean age 46.58 ± 15.43 years, 43.7% females) were investigated retrospectively in terms of clinical manifestations, rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), antinuclear antibody (ANA), and vitamin D (25OHD) levels. Patients were grouped as low Brucella (<1/160), high Brucella (≥1/160) titers, and the control group consisted of Brucella negative patients. Clinical manifestations, RF, anti-CCP, ANA, and 25 OHD levels were compared among the three groups. Correlation analysis was performed between autoimmune markers and 25OHD levels. RESULTS: The most common symptom among all Brucella seropositive patients was polyarthralgia (57.7%). RF positivity was found higher in two patient-groups than the control group (p = 0.008). Anti-CCP positivity was found higher in patient-groups than the control group (p <0.001). ANA levels were similar among the three groups (p = 0.077). Median 25OHD levels were found significantly lower in patient-groups than the control group (p <0.001). No correlation was found among vitamin D, RF, anti-CCP, and ANA levels (p = 0.501, p = 0.613 and p = 0.616, respectively). CONCLUSIONS: Increased rates of RF, anti-CCP; and decreased 25OHD levels in Brucella seropositive patients. It is important to consider brucellosis in the differential diagnosis of patients with rheumatologic manifestations in the presence of autoimmune markers. KEY WORDS: Anti-nuclear anti-body, Anti-cyclic citrullinated peptide, Brucella, Rheumatoid factor, Vitamin D.

The clinical significance of anti-DFS70 autoantibodies and its correlation with Vitamin D levels.

OBJECTIVE: This study aims to investigate the clinical significance of anti-dense fine speckled 70 (DFS70) autoantibodies and its association with systemic autoimmune rheumatic diseases (SARD) related autoimmune markers and Vitamin D levels. METHODS: The study group consisted of 281 (mean age±SD: 45.31±15.89 years; 88.3% female) anti-DFS70 autoantibody-positive patients. All patients' sera in the study group were tested by ANA HEp-2 indirect immunofluorescent antibody (IIF) and immunoblotting (IB) methods (Euroimmun AG, Lübeck, Germany). Anti-DFS70 antibody-positive patients were divided into two subgroups. Anti-DFS70 antibody-positive patients with SARD were assigned as Group 1 (n=43), anti-DFS70 antibody-positive patients without SARD were assigned as Group 2 (n=238). A control group with anti-DFS70 negative patients with SARD were assigned as Group 3 (n=49, mean age±SD: 49.86±12.08; 79.6% female). The clinical characteristics, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), neutrophil/lymphocyte ratio, thrombocyte/lymphocyte ratio (TLR), rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), and 25-hydroxyvitamin D3 (25OHD3) levels were compared between three groups. RESULTS: The majority (61.9%) of anti-DFS70 antibody positive patients had no specific diagnosis. Other systemic diseases were detected as allergic diseases (10.0%), hematological abnormalities (5.0%), thyroid diseases (3.6%), gastrointestinal system diseases (1.8%), malignancies (1.4%), and infections (1.1%). ESR, CRP levels, and TLR were lower in Group 2 than Groups 1 and 3 (p<0.05). RF and anti-CCP positivity rates were lower in Group 2 when compared with Groups 1 and 3 (p<0.05). 25OHD3 levels did not differ between three groups (p=0.103). CONCLUSION: We observed that anti-DFS70 autoantibody may be associated with organ-specific autoimmune diseases, allergic diseases, and hematological disorders. Therefore, it is essential to evaluate these pathologies in patients positive for anti-DFS70 antibodies.

Erythrocyte Autoantibody Positivity in Serological Cross-matching.

OBJECTIVE: To investigate the erythrocyte autoantibody positivity detected in the serological cross-matching (XM), and its  possible effects on salient hemogram parameters. STUDY DESIGN: A descriptive study. PLACE AND DURATION OF STUDY: Balikesir Atatürk City Hospital's Blood Transfusion Centre, Faculty of Medicine, Department of Anesthesiology and Reanimation, Balikesir University, Turkey, from 2017 to 2018. METHODOLOGY: Erythrocyte autoantibody positivity, which was detected in the traditional serological cross-matching for a pre-transfusion laboratory test were analysed retrospectively. Later, hemogram changes in the previous (no erythrocyte autoantibodies) and following (erythrocyte autoantibodies present) transfusions were investigated using statistical methods. RESULTS: Erythrocyte autoantibody positivity rate was 10.16% (342/3,365). There was no statistically significant difference in the increase of hemoglobin, hematocrit, and red blood cell between the period when erythrocyte autoantibodies were detected or not, (p = 0.27, 0.13, and 0.09, respectively). CONCLUSION: Erythrocyte autoantibodies positivity found on routine cross-match exmination, which must be considered together with parameters such as previous transfusion history, other pre-transfusion laboratory test results, and clinical presentation and management. Key Words: Transfusion, Erythrocye autoantibody, Alloantibody, Hemogram, Cross-matching.